BioSpace News Archive

Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and six months ended May 31, 2020. All dollar amounts referenced herein are in United States dollars unle

New projections released by PolicyLab at Children’s Hospital of Philadelphia forecast a continued surge in COVID-19 cases over the next four weeks in many areas of the country, with renewed risk spreading into the Northeast and Midwest, threatening our ability to safely reopen schools and universities if strong mitigation policies are not instituted.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the second quarter 2020 on Thursday, July 30, 2020, following the close of the market. The company will discuss these results in a conference call scheduled for 3 PM Pacific Time (6 P

Profound Medical Corp. is pleased to announce the pricing of an underwritten public offering of 2,758,621 common shares of the Company, at a price of US$14.50 per Common Share.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, announced today that The New England Journal of Medicine has published positive results from a Phase 2b trial of its investigational drug topical roflumilast cream

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced the closing of a registered direct offering of 145,838,979 ordinary shares, par value $0.0001 per share (the “Ordinary Shares”), to certain existing investors

TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced registered direct offering, with gross proceeds of approximately $10.5 million before deducting fees and other estimated offering expenses.

Lyfebulb, a patient empowerment platform, in partnership with Orexo, a global leader in the addictive disorders field, invites entrepreneurs to apply now through August 7th for the Lyfebulb-Orexo Innovation Challenge

AdaptHealth Corp., a leading provider of home medical equipment, supplies and related services in the United States, announced that its subsidiary, AdaptHealth LLC, has priced an offering of $350.0 million aggregate principal amount of 6.125% senior notes due 2028.

Perimeter Medical Imaging AI (TSXV:PINK) today announced the initiation of its ATLAS AI project that will collect images of breast tumors to both train and test their ImgAssist AI technology which is currently under development. This technology is designed to utilize a machine learning model to help surgeons identify, in real-time, if cancer